In vivo amplification of the androgen receptor gene and progression of human prostate cancer

Nature Genetics

Volumn 9, Issue 4, 1995, Pages 401-406

  Visakorpi, Tapio ^a,b   Hyytinen, Eija ^a   Koivisto, Pasi ^a   Tanner, Minna ^a   Keinänen, Riitta ^a   Palmberg, Christian ^a   Palotie, Aarno ^c   Tammela, Teuvo ^a   Isola, Jorma ^a   Kallioniemi, Olli P ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CHROMOSOME XQ; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; DRUG RESISTANCE; GENE AMPLIFICATION; HUMAN; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SUPPORT, NON-U.S. GOV'T; X CHROMOSOME;

EID: 0028944138     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng0495-401     Document Type: Article

References (30)

1. Boring, C.C., Squires, T.S. & Tong, T. Cancer Statistics, 1993 CA. Cancer J. Clin. 43, 7-26 (1993).
2. Gittes, R.F. Carcinoma of the prostate. New Engl. J. Med. 324, 236-245 (1991).
3. Stearn, M.E. & McGarvey, T. Biology of disease. Prostate cancer: therapeutics, diagnostic, and basic studies. Lab. Invest. 67, 540-552 (1992).
4. Berges, R.R., Furuya, Y., Remington, L., English, H.F., Jacks, T.& Isaacs, J.T. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. natn. Acad. Sci. U.S.A. 90, 8910-8914 (1993).
5. Labrie, F., Belanger, A., Dupont, A., Luu-The, V., Simard, J. & Labrie, C. Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med. 16, 475-492 (1993).
6. Culig, Z. et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.Molec. Endocrinol. 7, 1541-1550 (1993).
7. 24-18) in the androgen receptor gene In human prostate cancer. Biochem. Biophys. Res. Comm. 198, 74-80 (1994).
8. Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173, 534-540 (1990).
9. Thompson, T.C. Growth factors and oncogenes in prostate cancer. Cancer Cells 2, 345-354 (1990).
10. Kallioniemi, A. et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumours. Science 258, 818-821 (1992).
11. Kallioniemi, O.-P. et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumours. Genes Chrom. Cancer 10, 231-243 (1994).
12. Lafreniere, R.G. et al. Physical mapping of 60 DNA markers in the p21.1-21.3 region of the human X chromosome. Genomics 11, 352-363 (1991).
13. Gaddipati, J.P., McLeod, D.G. & Heidenberg, H.B. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54, 2861-2864 (1994).
14. Kellens, R.E. Gene amplificatlon in mammalian cells. A comprehensive guide. (Marcel Dekker, Inc., New York, 1993).
15. Nowell, P.C. Mechanisms of tumour progression. Cancer Res. 46, 2203-2207 (1986).
16. Dennis, L. Role of maximal androgen blockade in advanced prostate cancer. Prostate (suppl) 5, 17-22 (1994).
17. Crawford, E.D. et al. A controlled trial of leuprolide with and without flutamlde in prostatic carcinoma. New Engl. J. Med. 321, 419-424 (1989).
18. Corvi, R., Amler, L.C., Savelyeva, L., Gehring, M. & Schwab, M. MYCN is retained in single copy at chromosome 2 band p23-p24 during amplification in human neuroblastoma cells. Proc. natn. Acad. Sci. U.S.A. 91, 5523-5527 (1994).
19. Visakorpi, T. et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 55, 342-347 (1995).
20. Cher, M.L., MacGrogan, D., Bookstein, R., Brown, J.A., Jenkins, R.B. & Jensen, R. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer.Genes Chrom. Cancer 11, 153-162 (1994).
21. Tanner, M. et al. Increased copy number at 20q13 in breast cancer: defining the minimal region and exclusion of candidate genes. Cancer Res. 54, 2457-2460 (1994).
22. Sambrook, J., Fritsch, E.F. & Maniatis, T. Molecular Cloning: A Laboratory Manual (Cold Spring Habor Laboratory Press, Cold Spring Harbor, (1989).
23. Hyytinen, E., Visakorpi, T., Kallioniemi, A., Kallioniemi, O.-P. & Isola, J. Improved technique for analysis of formalin-fixed paraffin-embedded tumours by fluorescence in situ hybridization. Cytometry 16, 93-99 (1994).
24. Kallioniemi, O.P. et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. natn. Acad. Sci. U.S.A. 88, 5321-5325 (1992).
25. Ihalainen, J., Siitari, H., Laine, S., Syvänen, A.C. & Palotie, A. Towards automatic detection of point mutations: use of scintillating microplates in solid-phase minisequencing. Biotechniques 16, 938-943 (1994).
26. Dixon, W.J. BMDP Statistical Software (University of California Press, Los Angeles, 1981).
27. Sandberg, A.A. Chromosomal abnormalities and related events in prostate cancer. Hum. Pathol. 23, 368-380 (1992).
28. Rinker-Schaeffer, C.W. et al. Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res. 54, 6249-6256 (1994).
29. Isaacs, W.B., Bova, G.S., Morton, R.A., Bussemakers, M.J.G., Brooks, J.D. & Ewing, C.M. Molecular biology of prostate cancer. Semin. Oncol. 21, 514-521 (1994).
30. Macoska, J.A., Micale, M.A., Sakr, W.A., Benson, P.D. & Wolman, S.R. Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis. Genes Chrom. Cancer 8, 88-97 (1993).